FDA Accepts NDA for Vonoprazan (Voquenza) in Non-Erosive GER

The NDA submission was supported by positive data from the phase 3 PHALCON-NERD-301 study and has been assigned a standard 10-month review with a PDUFA target action date of July 19, 2024.

Related Keywords

, Azmi Nabulsi , Drug Administration , Phathom Pharmaceuticals Announces Positive Topline , Phathom Pharmaceuticals , Phathom Pharmaceuticals Announces , Phathom Pharmaceuticals Announces Vonoprazan , Phathom Pharmaceutical , Prescription Drug User Fee Act , New Drug Application , Tablets New Drug Application , Heartburn Associated , Evaluating Daily Dosing , Gerd , Non Erosive Gerd , Gastroesophageal Reflux Disease , Phalcon Nerd 301 , Heartburn , Phase 3 , Study , Trial , Vonoprazan , Voquenza ,